MarkA.HlatkyMD

Adult Congenital Heart Disease

Professor, Health Research & Policy, Stanford University Medical Center

Dr. Hlatky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Duke University HospitalFellowship, Cardiovascular Disease, 1981 - 1983
University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 1976 - 1979
Perelman School of Medicine at the University of PennsylvaniaClass of 1976

PubMed

Cost analysis of CYP2C19 genetic testing in percutaneous coronary intervention patients.
Samuel Huxley, James Moriarty, Mark A Hlatky, Ryan Lennon, Kent Bailey
The Pharmacogenomics Journal. 2024-10-08
Low-density lipoprotein cholesterol response to statins according to comorbidities and co-medications: A population-based study.
Giulia Corn, Marie Lund, Niklas W Andersson, Tine L Dohlmann, Mark A Hlatky
American Heart Journal. 2024-08-01
1 citations
Chronic Hypertension During Pregnancy: Prevalence and Treatment in the United States, 2008-2021.
Stephanie A Leonard, Sara Siadat, Elliott K Main, Krista F Huybrechts, Yasser Y El-Sayed
Hypertension. 2024-08-01

Journal Articles

Association of Adverse Pregnancy Outcomes with Risk of Atherosclerotic Cardiovascular Disease in Postmenopausal Women
Mark A Hlatky, Joann E Manson, JAMA Cardiology
Reduced Risk of Gastrointestinal Bleeding Associated with Proton Pump Inhibitor Therapy in Patients Treated with Dual Antiplatelet Therapy After Myocardial Infarction
Mark Hlatky, MD, European Heart Journal
Mini Focus on Diabetes Original Investigation Hypoglycemia and Elevated Troponin in Patients with Diabetes and Coronary Artery Disease
Brendan M Everett, Mark A Hlatky, Robert L Frye, Trevor J Orchard, Deepak L Bhatt, ScienceDirect
Original Investigation Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization
Michael J Domanski, Valentin Fuster, Mark A Hlatky, Gregg W Stone, ScienceDirect
Join now to see all

Lectures

Debate Con: PCSK9 Inhibitors: Is the Benefit Worth the Cost?
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
Pre-eclampsia: a Vascular Disease Across the Lifespan
2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019

Other

Mini-Focus Issue: Payer Issues and Patient Access Clinical Research Innovation in Heart Failure Treatment: Life Expectancy, Disability, and Health Disparities
Mark Hlatky, MD, ScienceDirect
https://www.doximity.com/articles/ca2085bc-9d3f-4f5c-a325-ae517839fd1a
UpToDate, Wolters Kluwer Health - 2013-02-15

Vitamin D and Statins: Supplements May Not Help Ease Muscle Pain, Side EffectsNovember 29th, 2022
Vitamin D Doesn’t Reduce Statin-Associated Muscle Symptoms: VITALNovember 25th, 2022
Vitamin D Ruled Out as Solution to Statin IntoleranceNovember 23rd, 2022
Join now to see all

Improved Estimates Of The Comparative Treatment Effects Of CABG And PCINational Heart, Lung, And Blood Institute2009–2010
Economic Outcomes Of Treatment Strategies In Bar1-2National Heart, Lung, And Blood Institute2000–2006
COST And Quality Of Life Outcomes After PTCA Or CABGNational Heart, Lung, And Blood Institute1997–2000
Clinical Research Training ProgramNational Heart, Lung, And Blood Institute1999
Cardiac Arrhythmia PORTAgency For Healthcare Research And Quality1994–1998